-
- Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunct...
- 10월 05일 15:35
-
- Andersen Global Enhances Pakistan Legal Presence with New Member Firm
- Andersen Global strengthens its legal presence in Pakistan as Samdani & Qureshi, a collaborating firm since 2021, rebrands to Andersen Legal in Pakistan and is the latest member firm to join the organization. Headquartered in Islamabad, Andersen L...
- 10월 05일 15:15
-
- Linesight Appoints John Butler as CEO
- Linesight, the global construction consultancy, today announced the appointment of John Butler as Chief Executive Officer, effective 1 January 2027. Butler will succeed Paul Boylan, who will remain closely involved with Linesight and its clients a...
- 10월 05일 12:45
